The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain

Clinical Rheumatology

Volumn 33, Issue 4, 2014, Pages 451-459

  Younger, Jarred ^a   Parkitny, Luke ^a   McLain, David ^b  

^a STANFORD UNIVERSITY   (United States)

^b McLain Medical Asso   (United States)

Author keywords

Anti inflammatory; Chronic pain; Fibromyalgia; Glial cell modulators; Low dose naltrexone; Microglia

Indexed keywords

ANTIINFLAMMATORY AGENT; NALTREXONE;

ANALGESIA; ANTIINFLAMMATORY ACTIVITY; BODY MASS; CHRONIC PAIN; CLINICAL RESEARCH; CLINICAL TRIAL (TOPIC); COMPLEX REGIONAL PAIN SYNDROME; CROHN DISEASE; DISEASE SEVERITY; DRUG COST; DRUG EFFICACY; DRUG MECHANISM; ERYTHROCYTE SEDIMENTATION RATE; FIBROMYALGIA; FOLLOW UP; GLIA CELL; HEADACHE; HEALTH INSURANCE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; INFLAMMATORY DISEASE; KIDNEY FAILURE; LIVER FUNCTION; LOW DRUG DOSE; LUPUS VULGARIS; MICROGLIA; MULTIPLE SCLEROSIS; NIGHTMARE; NONHUMAN; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; RHEUMATIC POLYMYALGIA; RHEUMATOID ARTHRITIS; SLEEP PATTERN; STEREOISOMERISM; TUMOR GROWTH; UNSPECIFIED SIDE EFFECT; VIVID DREAM; WITHDRAWAL SYNDROME; GLIA;

ANTI-INFLAMMATORY AGENTS; CHRONIC PAIN; FIBROMYALGIA; HUMANS; NALTREXONE; NEUROGLIA;

EID: 84898912209     PISSN: 07703198     EISSN: 14349949     Source Type: Journal    
DOI: 10.1007/s10067-014-2517-2     Document Type: Review

References (55)

1. Greeley JD, Lê AD, Poulos CX, Cappell H (1988) " Paradoxical" analgesia induced by naloxone and naltrexone. Psychopharmacology (Berlin) 96(1):36-39
2. Burns LH, Wang HY (2010) Ultra-low-dose naloxone or naltrexone to improve opioid analgesia: the history, the mystery and a novel approach clinical medicine insights
3. Davis M, Goforth HW, Gamier P (2013) Oxycodone combined with opioid receptor antagonists: efficacy and safety. Expert Opin Drug Saf 12(3):389-402
4. Resnick RB, Volavka J, Freedman AM, Thomas M (1974) Studies of EN-1639A (naltrexone): a new narcotic antagonist. Am J Psychiatry 131(6):646-650
5. Verebey K, Mulé SJ (1975) Naltrexone pharmacology, pharmacokinetics, and metabolism: current status. Am J Drug Alcohol Abuse 2(3-4):357-363
6. Gold MS, Dackis CA, Pottash AL, Sternbach HH, Annitto WJ, Martin D, Dackis MP (1982) Naltrexone, opiate addiction, and endorphins. Med Res Rev 2(3):211-246
7. Smith JP, Bingaman SI, Ruggiero F, Mauger DT, Mukherjee A, McGovern CO, Zagon IS (2011) Therapy with the opioid antagonist naltrexone promotes mucosal healing in active Crohn's disease: a randomized placebo-controlled trial. Dig Dis Sci 56(7):2088-2097
8. Cree BA, Kornyeyeva E, Goodin DS (2010) Pilot trial of low-dose naltrexone and quality of life in multiple sclerosis. Ann Neurol 68(2):145-150
9. Younger J, Noor N, McCue R, Mackey S (2013) Low-dose naltrexone for the treatment of fibromyalgia: findings of a small, randomized, double-blind, placebo-controlled, counterbalanced, crossover trial assessing daily pain levels. Arthritis Rheum 65(2):529-538
10. Bihari B (2013) Bernard Bihari, MD: low-dose naltrexone for normalizing immune system function. Altern Ther Health Med 19(2):56-65
11. Zagon IS, McLaughlin PJ (1989) Opioid antagonist modulation of murine neuroblastoma: a profile of cell proliferation and opioid peptides and receptors. Brain Res 480(1-2):16-28
12. Smith JP, Stock H, Bingaman S, Mauger D, Rogosnitzky M, Zagon IS (2007) Low-dose naltrexone therapy improves active Crohn's disease. Am J Gastroenterol 102(4):820-828
13. Clauw DJ, Arnold LM, McCarberg BH, FibroCollaborative (2011) The science of fibromyalgia. Mayo Clin Proc 86(9):907-911
14. Wallace DJ (2006) Is there a role for cytokine based therapies in fibromyalgia. Curr Pharm Des 12(1):17-22
15. Younger J, Mackey S (2009) Fibromyalgia symptoms are reduced by low-dose naltrexone: a pilot study. Pain Med 10(4):663-672
16. Wang D, Sun X, Sadee W (2007) Different effects of opioid antagonists on mu-, delta-, and kappa-opioid receptors with and without agonist pretreatment. J Pharmacol Exp Ther 321(2):544-552
17. Watkins LR, Hutchinson MR, Ledeboer A, Wieseler-Frank J, Milligan ED, Maier SF (2007) Norman cousins lecture. Glia as the "bad guys": implications for improving clinical pain control and the clinical utility of opioids. Brain Behav Immun 21(2):131-146
18. McCusker RH, Kelley KW (2013) Immune-neural connections: how the immune system's response to infectious agents influences behavior. J Exp Biol 216(Pt 1):84-98
19. Dantzer R (2007) Twenty years of research on cytokine-induced sickness behavior Brain, behavior, and immunity
20. Kelley KW, Bluthé RM, Dantzer R, Zhou JH, Shen WH, Johnson RW, Broussard SR (2003) Cytokine-induced sickness behavior. Brain Behav Immun 17(Suppl 1):S112-S118
21. Wieseler-Frank J, Maier SF, Watkins LR (2005) Immune-to-brain communication dynamically modulates pain: physiological and pathological consequences. Brain Behav Immun 19(2):104-111
22. Hutchinson MR et al (2008) Non-stereoselective reversal of neuropathic pain by naloxone and naltrexone: involvement of toll-like receptor 4 (TLR4). Eur J Neurosci 28(1):20-29
23. Liu B, Du L, Hong JS (2000) Naloxone protects rat dopaminergic neurons against inflammatory damage through inhibition of microglia activation and superoxide generation. J Pharmacol Exp Ther 293(2):607-617
24. Chang RC, Rota C, Glover RE, Mason RP, Hong JS (2000) A novel effect of an opioid receptor antagonist, naloxone, on the production of reactive oxygen species by microglia: a study by electron paramagnetic resonance spectroscopy. Brain Res 854(1-2):224-229
25. Liu SL, Li YH, Shi GY, Chen YH, Huang CW, Hong JS, Wu HL (2006) A novel inhibitory effect of naloxone on macrophage activation and atherosclerosis formation in mice. J Am Coll Cardiol 48(9):1871-1879
26. Valentino RJ, Katz JL, Medzihradsky F, Woods JH (1983) Receptor binding, antagonist, and withdrawal precipitating properties of opiate antagonists. Life Sci 32(25):2887-2896
27. Lewis SS, Loram LC, Hutchinson MR, Li CM, Zhang Y, Maier SF, Huang Y, Rice KC, Watkins LR (2012) (+)-naloxone, an opioid-inactive toll-like receptor 4 signaling inhibitor, reverses multiple models of chronic neuropathic pain in rats. J Pain 13(5):498-506
28. Stevens CW, Aravind S, Das S, Davis RL (2013) Pharmacological characterization of LPS and opioid interactions at the toll-like receptor 4. Br J Pharmacol 168(6):1421-1429
29. Fukagawa H, Koyama T, Kakuyama M, Fukuda K (2013) Microglial activation involved in morphine tolerance is not mediated by toll-like receptor 4. J Anesth 27(1):93-97
30. Block L, Björklund U, Westerlund A, Jörneberg P, Biber B, Hansson E (2013) A new concept affecting restoration of inflammation-reactive astrocytes. Neuroscience 250:536-545
31. Wang Q, Zhou H, Gao H, Chen SH, Chu CH, Wilson B, Hong JS (2012) Naloxone inhibits immune cell function by suppressing superoxide production through a direct interaction with gp91phox subunit of NADPH oxidase. J Neuroinflammation 9:32
32. Zagon IS, Verderame MF, McLaughlin PJ (2002) The biology of the opioid growth factor receptor (OGFr). Brain Res Brain Res Rev 38(3):351-376
33. Sharma R, Rauchhaus M, Ponikowski PP, Varney S, Poole-Wilson PA, Mann DL, Coats AJ, Anker SD (2000) The relationship of the erythrocyte sedimentation rate to inflammatory cytokines and survival in patients with chronic heart failure treated with angiotensin-converting enzyme inhibitors. J Am Coll Cardiol 36(2):523-528
34. García JJ, Cidoncha A, Bote ME, Hinchado MD, Ortega E (2013) Altered profile of chemokines in fibromyalgia patients. Ann Clin Biochem 6(7):425-435
35. Xiao Y, Haynes WL, Michalek JE, Russell IJ (2013) Elevated serum high-sensitivity C-reactive protein levels in fibromyalgia syndrome patients correlate with body mass index, interleukin-6, interleukin-8, erythrocyte sedimentation rate. Rheumatol Int 33(5):1259-1264
36. Smith JP, Field D, Bingaman SI, Evans R, Mauger DT (2013) Safety and tolerability of low-dose naltrexone therapy in children with moderate to severe Crohn's disease: a pilot study. J Clin Gastroenterol 47(4):339-345
37. Sharafaddinzadeh N, Moghtaderi A, Kashipazha D, Majdinasab N, Shalbafan B (2010) The effect of low-dose naltrexone on quality of life of patients with multiple sclerosis: a randomized placebo-controlled trial. Mult Scler 16(8):964-969
38. Chopra P, Cooper MS (2013) Treatment of complex regional pain syndrome (CRPS) using low dose naltrexone (LDN). J Neuroimmune Pharm 8(3):470-476
39. Parkitny L, McAuley JH, Di Pietro F, Stanton TR, O'Connell NE, Marinus J, van Hilten JJ, Moseley GL (2013) Inflammation in complex regional pain syndrome: a systematic review and meta-analysis. Neurology 80(1):106-117
40. Brown N, Panksepp J (2009) Low-dose naltrexone for disease prevention and quality of life. Med Hypotheses 72(3):333-337
41. Tempel A, Gardner EL, Zukin RS (1985) Neurochemical and functional correlates of naltrexone-induced opiate receptor up-regulation. J Pharmacol Exp Ther 232(2):439-444
42. Zagon IS, McLaughlin PJ (1995) Gene-peptide relationships in the developing rat brain: the response of preproenkephalin mRNA and [Met5]-enkephalin to acute opioid antagonist (naltrexone) exposure. Brain Res Mol Brain Res 33(1):111-120
43. Donahue RN, McLaughlin PJ, Zagon IS (2011) Low-dose naltrexone targets the opioid growth factor-opioid growth factor receptor pathway to inhibit cell proliferation: mechanistic evidence from a tissue culture model. Exp Biol Med (Maywood) 236(9):1036-1050
44. Kayser V, Besson JM, Guilbaud G (1987) Paradoxical hyperalgesic effect of exceedingly low doses of systemic morphine in an animal model of persistent pain (Freund's adjuvant-induced arthritic rats). Brain Res 414(1):155-157
45. Galeotti N, Stefano GB, Guarna M, Bianchi E, Ghelardini C (2006) Signaling pathway of morphine induced acute thermal hyperalgesia in mice. Pain 123(3):294-305
46. Physicians' Desk Reference 2013 (67th ed) Montvale, NJ: PDR
47. Pini LA, Ferretti C, Trenti T, Ferrari A, Sternieri E (1991) Effects of long-term treatment with naltrexone on hepatic enzyme activity. Drug Metabol Drug Interact 9(2):161-174
48. Zagon IS, Donahue R, McLaughlin PJ (2013) Targeting the opioid growth factor: opioid growth factor receptor axis for treatment of human ovarian cancer. Exp Biol Med (Maywood) 238(5):579-587
49. Casha S, Zygun D, McGowan MD, Bains I, Yong VW, Hurlbert RJ (2012) Results of a phase II placebo-controlled randomized trial of minocycline in acute spinal cord injury. Brain 135(Pt 4):1224-1236
50. Zhou Q, Price DD, Callam CS, Woodruff MA, Verne GN (2011) Effects of the N-methyl-D-aspartate receptor on temporal summation of second pain (wind-up) in irritable bowel syndrome. J Pain 12(2):297-303
51. Swift RM (2013) Naltrexone and nalmefene: any meaningful difference? Biol Psychiatry 73(8):700-701
52. Tang C, Godfrey T, Stawell R, Nikpour M (2012) Hydroxychloroquine in lupus: emerging evidence supporting multiple beneficial effects. Int Med J 42(9):968-978
53. Steere AC, Angelis SM (2006) Therapy for Lyme arthritis: strategies for the treatment of antibiotic-refractory arthritis. Arthritis Rheum 54(10):3079-3086
54. Choi DK, Koppula S, Suk K (2011) Inhibitors of microglial neurotoxicity: focus on natural products. Molecules 16(2):1021-1043
55. Moore A, Wilkinson S (2009) The promise of low dose naltrexone. McFarland, North Carolina